Assessing the clinical benefit of systemic adjuvant therapies for early breast cancer
- Weitere Titel
-
Bestimmung des klinischen Nutzens systemischer adjuvanter Therapien beim frühen Mammakarzinom
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Geburtshilfe und Frauenheilkunde, 77.2017, Nr. 10, S. 1079–1087, doi:10.1055/s-0043-119542
- Schlagwort
-
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2017
- Urheber
- URN
-
urn:nbn:de:hebis:30:3-442927
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:49 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Möbus, Volker
- Hell, Susanne
- Schmidt, Marcus
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2017
Ähnliche Objekte (12)
Adjuvant therapies of cancer
Adjuvant therapies and markers of post-surgical minimal residual disease, 2.. Adjuvant therapies of the various primary tumors
Adjuvant therapy of primary breast cancer
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
The influence of radio-immunotherapy on the tumor microenvironment of breast-to-brain metastasis and the investigation of novel adjuvant therapies
Adjuvant therapy of breast cancer IV : with 71 tables
Adjuvant therapy of breast cancer V : with 71 tables
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry
Adjuvant therapy of primary breast cancer VI : with 60 tables
Update breast cancer 2023 Part 3 – expert opinions of early stage breast cancer therapies
Update breast cancer 2023 part 3: expert opinions of early stage breast cancer therapies
Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases
Adjuvant therapies of cancer
Adjuvant therapies and markers of post-surgical minimal residual disease, 2.. Adjuvant therapies of the various primary tumors
Adjuvant therapy of primary breast cancer
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
The influence of radio-immunotherapy on the tumor microenvironment of breast-to-brain metastasis and the investigation of novel adjuvant therapies
Adjuvant therapy of breast cancer IV : with 71 tables
Adjuvant therapy of breast cancer V : with 71 tables
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry
Adjuvant therapy of primary breast cancer VI : with 60 tables
Update breast cancer 2023 Part 3 – expert opinions of early stage breast cancer therapies
Update breast cancer 2023 part 3: expert opinions of early stage breast cancer therapies
Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases
Adjuvant therapies of cancer
Adjuvant therapies and markers of post-surgical minimal residual disease, 2.. Adjuvant therapies of the various primary tumors
Adjuvant therapy of primary breast cancer
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
The influence of radio-immunotherapy on the tumor microenvironment of breast-to-brain metastasis and the investigation of novel adjuvant therapies
Adjuvant therapy of breast cancer IV : with 71 tables
Adjuvant therapy of breast cancer V : with 71 tables
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry
Adjuvant therapy of primary breast cancer VI : with 60 tables
Update breast cancer 2023 Part 3 – expert opinions of early stage breast cancer therapies
Update breast cancer 2023 part 3: expert opinions of early stage breast cancer therapies